AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical study to explore the pharmacokinetics of balcinrenone/dapagliflozin under different conditions. Officially titled ‘A Phase I, Randomised, Single-dose, Open-label, 3-period, 3-treatment, 3-way Crossover Study to Assess the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants,’ the study aims to understand how food and a P-gp inhibitor affect the drug’s absorption and processing in the body.
The study tests two main interventions: the combination drug balcinrenone/dapagliflozin, and quinidine, a P-gp inhibitor. The goal is to determine how these drugs behave in the body when taken with food, without food, and with a P-gp inhibitor.
This interventional study is designed as a randomized, open-label, crossover trial with no masking. Participants will receive treatments in different sequences to compare the effects of the interventions. The primary purpose is to gather data on drug absorption and metabolism.
The study began on May 20, 2025, with primary completion expected shortly after. The latest update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection.
For investors, this study could influence AstraZeneca’s stock performance by potentially expanding their drug portfolio if successful. The results could also impact investor sentiment positively, given the innovative nature of the study. Competitors in the pharmaceutical industry may closely watch these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.